Disclosed herein are bacteria engineered to treat diseases associated with hyperammonemia and methods of use thereof. Specifically, the bacteria are engineered to comprise a racemase to enable the detection of non-naturally occurring metabolites as an indication that the engineered bacteria are effectively converting ammonia.

The present invention relates to a method of manufacturing glufosinate, comprising the step of enzymatically cleaving off a carbamoyl moiety of a carbamoyl amino acid compound.